Development of biologics, such as monoclonal antibodies and novel therapeutics, approval of products coupled with governments around the world increasingly investing in healthcare R&D to address the unmet care is anticipated to drive the market.
Development of biologics, such as monoclonal antibodies and novel therapeutics, approval of products coupled with governments around the world increasingly investing in healthcare R&D to address the unmet care is anticipated to drive the market.